Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
23.55
-0.40 (-1.67%)
At close: Jan 22, 2026, 4:00 PM EST
23.55
0.00 (0.00%)
After-hours: Jan 22, 2026, 6:09 PM EST
Zymeworks Revenue
Zymeworks had revenue of $27.61M in the quarter ending September 30, 2025, with 72.59% growth. This brings the company's revenue in the last twelve months to $134.48M, up 116.21% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$134.48M
Revenue Growth
+116.21%
P/S Ratio
13.17
Revenue / Employee
$470,213
Employees
286
Market Cap
1.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ZYME News
- 7 days ago - Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy - GlobeNewsWire
- 10 days ago - HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth - Seeking Alpha
- 11 days ago - Zymeworks Outlines Strategic Priorities and Outlook for 2026 - GlobeNewsWire
- 16 days ago - Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewsWire
- 7 weeks ago - Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - Zymeworks Announces Participation in Upcoming Conferences - GlobeNewsWire
- 2 months ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire